Oncology

Latest News

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com
Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

August 29th 2025

The 6-month progression-free survival rate for the combination therapy was 52.2%.

For rent sign | Image Credit: David Gales - stock.adobe.com
Housing Assistance May Help Renters With Cancer Better Withstand Medical Financial Strain

August 28th 2025

Patient with cancer undergoing chemotherapy | Image credit: RFBSIP – stock.adobe.com
Many Patients With Advanced Cancer Report Care Misaligned With Their Goals

August 25th 2025

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap
Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

August 21st 2025

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma
July 29th 2013

Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma

Dr Ribas opened this segment by discussing the new immunotherapy agents used in the treatment of metastatic melanoma. Specifically, he discussed the agents vemurafenib (Zelboraf), dabrafenib (Taflinar), and trametinib (Mekinist).
Segment 1- Introduction and Therapeutic Overview
July 29th 2013

Segment 1- Introduction and Therapeutic Overview

Panel moderator and AJMC co-editor-in-chief Dr Mark Fendrick introduced panelists Jennifer Malin, MD, PhD, manager and medical director of oncology, WellPoint; Jeffrey Weber, MD, PhD, senior member, H. Lee Moffitt Cancer Center Director, Donald A. Adam Comprehensive Melanoma Research Center; and Antoni Ribas, MD, PhD, Jonsson Comprehensive Cancer Center, UCLA.
Site Logo
July 22nd 2013

More Evidence Not All Prostate Cancers Need Treatment

In a study of older men who had died from causes other than prostate cancer, almost half were found to have prostate tumors. And up to half of those tumors detected on autopsy would have qualified for treatment had doctors known about them while the men lived, though none had been the cause of death.
Site Logo
July 19th 2013

Lung Cancer Screening Most Useful in High-risk People

Using low-dose CT scans to screen high-risk patients for lung tumors is far more effective at preventing lung cancer deaths than scanning those at low risk, according to a new analysis of over 53,000 volunteers.
Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models
July 18th 2013

Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models

In the final segment, panelists examine the use of companion diagnostics to determine proper patient utilization. Dr. Chernew asks if the required diagnostic testing is being appropriately used and if they are being covered by payers.
Segment 4: Reimbursement and Clinical Pathways
July 18th 2013

Segment 4: Reimbursement and Clinical Pathways

This segment of the panel discussion takes a closer look at the episode of cost for a patient going to a hospital versus a private office setting. Panelists agree that the cost of hospital care is not that much greater than in the office.
Segment 3: How Payers are assessing the Value of New Agents
July 18th 2013

Segment 3: How Payers are assessing the Value of New Agents

Dr. Chernew asks the panelists how payers address the value of these costly combination therapies when there are less expensive options available. Dr. Newcomer says that the drugs being discussed are, in fact, having a significant clinical effect.
Segment 2: Overview of Results from EMILIA and MARIANNE Trials
July 18th 2013

Segment 2: Overview of Results from EMILIA and MARIANNE Trials

In this clip, Dr. Swain and Dr. Newcomer discuss the results from the EMILIA trial. Dr. Swain notes that the survival benefit with the use of TDM-1 was five months.
Segment 1: Introduction and Patient Population
July 18th 2013

Segment 1: Introduction and Patient Population

Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.
Site Logo
July 12th 2013

Bill Pushes Legislation to Restore Medicare Funding for Cancer Treatments

A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels
Site Logo
July 11th 2013

Shared Decision Making Uncommon in PSA Screening

While American Urological Association and American College of Physician guidelines suggest shared-decision making in prostate specific antigen (PSA) screen testing, most patients have not had part in discussing those decisions.
Site Logo
July 3rd 2013

Trials Begin for New Novel Immunotherapy in Melanoma

A clinical research study at Rosewell Park Cancer Institute (RPCI) will be examining a new novel immunotherapy approach to treating advanced melanoma.
Site Logo
July 2nd 2013

Access to Insurance May Be Reason for Rising Thyroid Cancer Diagnosis

Episode 17 - Conclusion: Treatment Advancements and Final Remarks
July 2nd 2013

Episode 17 - Conclusion: Treatment Advancements and Final Remarks

Episode 16 - MRI Scans and MS
July 2nd 2013

Episode 16 - MRI Scans and MS

Episode 15 - Controlling Drug Prices and Working at the Population Level
July 2nd 2013

Episode 15 - Controlling Drug Prices and Working at the Population Level

Episode 14 - Concerns about Rising Costs of Treatment
July 2nd 2013

Episode 14 - Concerns about Rising Costs of Treatment

Episode 13 - Treatment Challenges for Progressive Disease
July 2nd 2013

Episode 13 - Treatment Challenges for Progressive Disease

Episode 12 - New MS Agents Challenged
July 2nd 2013

Episode 12 - New MS Agents Challenged

Episode 11 - Clinical Guidelines Vital to the Future of MS
July 2nd 2013

Episode 11 - Clinical Guidelines Vital to the Future of MS

Episode 10 - Treatment Complexities
July 2nd 2013

Episode 10 - Treatment Complexities

Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis
July 2nd 2013

Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis

Episode 8 - Long-Term Effects of Disease-Modifying Therapies
July 2nd 2013

Episode 8 - Long-Term Effects of Disease-Modifying Therapies

Episode 7 - Increased Monetary Costs of Multiple Sclerosis
July 2nd 2013

Episode 7 - Increased Monetary Costs of Multiple Sclerosis

Episode 4- Characterizing Multiple Sclerosis
July 2nd 2013

Episode 4- Characterizing Multiple Sclerosis

Episode 3- Exploring the Etiology of Multiple Sclerosis
July 2nd 2013

Episode 3- Exploring the Etiology of Multiple Sclerosis

Episode 6 - Discussing the Pathophysiology of MS
July 2nd 2013

Episode 6 - Discussing the Pathophysiology of MS

Episode 5 - Elucidating the Economic Burden of MS
July 2nd 2013

Episode 5 - Elucidating the Economic Burden of MS

Episode 2 - Elucidating the Patient's Starting Point in Care
July 2nd 2013

Episode 2 - Elucidating the Patient's Starting Point in Care

Episode 1 - The Changing Tides of Multiple Sclerosis: Where Do We Currently Stand?
July 2nd 2013

Episode 1 - The Changing Tides of Multiple Sclerosis: Where Do We Currently Stand?

<1
...
173174175176177178179180181
...
188>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo